A Unique Approach
to Immunology
Alpine Immune Sciences is a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies. Launched in 2015, we have created and advanced multiple product candidates into clinical trials for inflammatory/autoimmune diseases and cancer, formed collaborations with world-class partners, and built a robust development pipeline.
Our scientific platform consists of unique protein engineering strategies, including the directed evolution of immune proteins into novel, multi-targeted therapeutics. With such differentiated candidates, we hope to improve outcomes in patients with cancer and severe inflammatory and autoimmune diseases.
Join us in the discovery and development of next-generation immunotherapies.
Current job openingsLearn more about Alpine
Alpine’s Pipeline
We have a diverse pipeline across inflammatory/autoimmune disease and immuno-oncology. For more information on our ongoing clinical trials please refer to the clinical trials portion of our website. For additional information please refer to our corporate filings, corporate presentations, and scientific publications.
Acazicolcept (ALPN-101)
Dual CD28/ICOS Costimulation Antagonist
Autoimmune Diseases
Davoceticept (ALPN-202)
Conditional (PD-L1-dependent) CD28 Costimulator and Dual Checkpoint (PD-L1/CTLA-4) Inhibitor
Oncology
ALPN-303
Dual BAFF/APRIL B cell cytokine antagonist
Autoimmune Diseases
Latest News
Alpine Immune Sciences Announces Pricing of $100 Million Public Offering
Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the pricing of its underwritten public offering of 13,606,000 shares of its common stock pursuant to its existing shelf registration statement. The shares of common stock are being offered…
Alpine Immune Sciences Announces Proposed Public Offering
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock and, in lieu of shares of common stock to certain investors that so choose…
Alpine Immune Sciences to Highlight Clinical Updates on Autoimmune and Immuno-Oncology Programs at Inaugural R&D Day
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced clinical updates from two wholly owned programs, ALPN-303 and davoceticept.
